Finance

Lists
Why is AMGN34 down 2,33%?
Dive Deeper
AMGN34:BVMF
Amgen Inc. BDR
75,52 R$
-2,33%
(-1,80) 1D
2 ოქტ, 16:56:00 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for AMGN34...
Open
75,76 R$
High
75,82 R$
Low
75,32 R$
Mkt. cap
217,90 მლრ.
Avg. vol.
376,00
Volume
112,00
52-wk high
83,06 R$
52-wk low
47,76 R$
Shares outstanding
540,63 მლნ.
No. of employees
32 ათ.
Open
75,76 R$
High
75,82 R$
Low
75,32 R$
Mkt. cap
217,90 მლრ.
Avg. vol.
376,00
Volume
112,00
52-wk high
83,06 R$
52-wk low
47,76 R$
Shares outstanding
540,63 მლნ.
No. of employees
32 ათ.
News stories
From web sources and news partners
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc. BDR
CEOრობერტ ეი ბრედუეი
Employees31,5 ათ.
Founded1980
Headquartersთაუზენდ-ოუკსი, კალიფორნია, ამერიკის შეერთებული შტატები
Sector-
Websiteamgen.com
Last report
4 აგვ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
6,29 US$ / 5,62 US$
+11,97%beat
Revenue / Est. (USD)
10,05 მლრდ. / 9,42 მლრდ.
+6,73%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
9,56 მლრდ.
9,87 მლრდ.
8,62 მლრდ.
10,05 მლრდ.
Cost of goods sold
2,74 მლრდ.
2,68 მლრდ.
2,50 მლრდ.
2,75 მლრდ.
Cost of revenue
2,74 მლრდ.
2,68 მლრდ.
2,50 მლრდ.
2,75 მლრდ.
Research and development expenses
1,90 მლრდ.
2,14 მლრდ.
1,72 მლრდ.
1,87 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,72 მლრდ.
1,95 მლრდ.
1,60 მლრდ.
1,74 მლრდ.
Operating expense
3,55 მლრდ.
4,18 მლრდ.
3,21 მლრდ.
3,73 მლრდ.
Total operating expenses
6,29 მლრდ.
6,85 მლრდ.
5,70 მლრდ.
6,48 მლრდ.
Operating income
3,26 მლრდ.
3,01 მლრდ.
2,91 მლრდ.
3,57 მლრდ.
Other non operating income
181,00 მლნ.
143,00 მლნ.
192,00 მლნ.
145,00 მლნ.
EBT including unusual items
3,92 მლრდ.
1,51 მლრდ.
2,08 მლრდ.
2,77 მლრდ.
EBT excluding unusual items
2,72 მლრდ.
2,51 მლრდ.
2,37 მლრდ.
3,06 მლრდ.
Income tax expense
705,00 მლნ.
181,00 მლნ.
265,00 მლნ.
393,00 მლნ.
Effective tax rate
17,98%
11,96%
12,72%
14,20%
Other operating expenses
-71,00 მლნ.
82,00 მლნ.
-113,00 მლნ.
116,00 მლნ.
Net income
3,22 მლრდ.
1,33 მლრდ.
1,82 მლრდ.
2,38 მლრდ.
Net profit margin
33,65%
13,51%
21,11%
23,62%
Earnings per share
5,64
5,29
5,15
6,29
Interest and investment income
-
408,00 მლნ.
-
-
Interest expense
-685,00 მლნ.
-1,06 მლრდ.
-657,00 მლნ.
-673,00 მლნ.
Net interest expenses
-685,00 მლნ.
-653,00 მლნ.
-657,00 მლნ.
-673,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
4,57 მლრდ.
4,02 მლრდ.
4,03 მლრდ.
4,69 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები